Skip to content
OpenCapital
Get started

Artiva Biotherapeutics, Inc. ARTV Cash And Cash Equivalents At Fair Value And Available For Sale Debt Securities At Fair Value Excluding Accrued Interest

Other financials

Income statement

See full
Revenue-—
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%—
Net margin-79.3%—

Returns & leverage

See full
Return on equity-67.9%—
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept artv:CashAndCashEquivalentsAtFairValueAndAvailableForSaleDebtSecuritiesAtFairValueExcludingAccruedInterest.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest?
Artiva Biotherapeutics, Inc. (ARTV) reported cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest of $86.78M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest changed year-over-year?
Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest decreased by 47.7% year-over-year, from $165.96M to $86.78M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s cash and cash equivalents at fair value and available for sale debt securities at fair value excluding accrued interest has grown at a 18.5% compound annual growth rate (CAGR), from $76.97M to $108.01M.